420 results on '"Lengfelder, Eva"'
Search Results
2. Akute myeloische Leukämie beim alten und geriatrischen Patienten
3. Treatment of Refractory and Relapsed APL
4. Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens
5. Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
6. A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia
7. Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines
8. Treatment of Refractory and Relapsed APL
9. Akute myeloische Leukämie beim alten und geriatrischen Patienten
10. Stammzellerkrankungen
11. Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma—experience at the Lymph Node Registry Kiel
12. Stammzellerkrankungen
13. In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival
14. DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding
15. Erkrankungen des Blutes
16. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
17. Interleukin-2 Bolus Infusion as Consolidation Therapy in 2nd Remission of Acute Myelocytic Leukemia
18. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial
19. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
20. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
21. Leitlinie - Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h��matologischer und onkologischer Erkrankungen
22. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen : ICD-10 D47.1
23. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h��matologischer und onkologischer Erkrankungen
24. Management of elderly patients with acute promyelocytic leukemia: progress and problems
25. Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
26. High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia
27. Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
28. Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
29. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
30. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study
31. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
32. Leitlinie : ICD10: C92.4 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
33. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions
34. RNA-sequencing of acute promyelocytic leukemia primary blasts reveals novel molecular biomarkers of early death events
35. Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
36. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
37. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
38. Problems With Up-Front Randomization in Clinical Trials
39. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group
40. Double Induction Containing Either Two Courses or One Course of High-Dose Cytarabine Plus Mitoxantrone and Postremission Therapy by Either Autologous Stem-Cell Transplantation or by Prolonged Maintenance for Acute Myeloid Leukemia
41. Diagnosis and Therapy of Polycythemia Vera
42. 6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and High-Dose Cytarabine and Mitoxantrone (HAM) for Induction, TAD for Consolidation, and Either Prolonged Maintenance by Reduced Monthly TAD or TAD-HAM-TAD and One Course of Intensive Consolidation by Sequential HAM in Adult Patients at All Ages With De Novo Acute Myeloid Leukemia (AML): A Randomized Trial of the German AML Cooperative Group
43. Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies
44. Interleukin-2 Bolus Infusion as Consolidation Therapy in 2nd Remission of Acute Myelocytic Leukemia
45. Leitlinie - ICD10: D45 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
46. Leitlinie - ICD-10 D47.1 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
47. Primäre Myelofibrose (PFM)
48. Essentielle (oder primäre) Thrombozythämie (ET)
49. Leitlinie : ICD10: C92.4 Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
50. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.